安定細胞株製品 » Human Recombinant H3 Histamine Receptor Stable Cell Line
CHO-K1/H3/Gα15 Stable Cell Line

Figure 1. Histamine-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/H3/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142, Molecular Devices) prior to being stimulated with agonist histamine. The intracellular calcium change was measured by FLIPR. The relative fluorescent units (RFU) were recorded and plotted against the log of the cumulative doses of histamine (Mean ± SEM, n = 3). The EC50 of histamine on this cell was 11.50 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response
Y is ∆RFU and starts at Bottom and goes to Top with a sigmoid shape.

CHO-K1/H3/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with histamine in CHO-K1/H3/Gα15 cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEB; Revvity) and intracellular cAMP in CHO-K1/H3/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of histamine on CHO-K1/H3/Gα15 cells was 24.68 nM.

CHO-K1/H3/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human histamine receptor H3 (H3) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
M00331
¥1,661,121.00

Ask us a question
Product Introduction
Product Description Recombinant CHO-K1 cells stably overexpress human histamine receptor H3 (H3) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Conditions
Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 400 μg/ml Geneticin (Cat. No. 10131-035, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies)
Complete Growth Medium Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 10% FBS
Freeze Medium-DATA 95% complete growth medium, 45% FBS (Cat. No. 10099-141, Life Technologies), 5% DMSO (Cat. No. D2650, Sigma)

Examples
  • CHO-K1/H3/Gα15 Stable Cell Line
  • CHO-K1/H3/Gα15 Stable Cell Line

    Figure 1. Histamine-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/H3/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142, Molecular Devices) prior to being stimulated with agonist histamine. The intracellular calcium change was measured by FLIPR. The relative fluorescent units (RFU) were recorded and plotted against the log of the cumulative doses of histamine (Mean ± SEM, n = 3). The EC50 of histamine on this cell was 11.50 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
    X is the logarithm of concentration. Y is the response
    Y is ∆RFU and starts at Bottom and goes to Top with a sigmoid shape.

  • CHO-K1/H3/Gα15 Stable Cell Line
  • CHO-K1/H3/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with histamine in CHO-K1/H3/Gα15 cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEB; Revvity) and intracellular cAMP in CHO-K1/H3/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of histamine on CHO-K1/H3/Gα15 cells was 24.68 nM.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.